CCL2 and breast carcinoma: It is also reported that high expression of a CCR2 ligand (CCL2) in tumors positively associates with the accumulation of TAMs in glioblastoma, squamous cell carcinoma, renal cell carcinoma (RCC), as well as ovarian, endometrial, lung, and breast cancer (47–53).